Positive Update on IMP761 Phase 1
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The study observed a dose-dependent immunosuppressive effect and significant reduction in T cell activity, suggesting potential efficacy in treating autoimmune conditions. The trial will continue as planned, with further updates expected in the first half of the following year, including data presentation at a major medical conference.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immutep
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
- TACTI-004 phase III trial enrolment continues at robust pace
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
- Immutep enters into Strategic Collaboration with Dr. Reddy's
- Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Later from Immutep
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Quarterly Activities Report Q2 FY26
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep